NCT05349890View on ClinicalTrials.gov

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

April 15, 2026

Study Completion Date

April 15, 2028

Conditions
Malignant Epithelial Neoplasms
Interventions
BIOLOGICAL

TCR-transduced T cells

TSA-reactive TCR-engineered T cells

DRUG

CDX-1140

Recombinant fully human IgG2κ monoclonal antibody

DRUG

Pembrolizumab

Humanized immunoglobulin G4 (IgG4) monoclonal antibody

Trial Locations (1)

97213

Providence Portland Medical Center, Portland

Sponsors

Collaborators (1)

Celldex Therapeutics
All Listed Sponsors
collaborator

Celldex Therapeutics

INDUSTRY

collaborator

Providence Cancer Center, Earle A. Chiles Research Institute

OTHER

lead

Providence Health & Services

OTHER

NCT05349890 - Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) | Biotech Hunter | Biotech Hunter